NCT03393806 - Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

October 9, 2019

Study Completion Date

January 6, 2020

Conditions

Asthma

Interventions

DRUG

GSK3772847

GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.

DRUG

Placebo

Commercially sourced sterile normal saline will be provided as Placebo

Trial Locations (18)

29609

GSK Investigational Site, Brest

34295

GSK Investigational Site, Montpellier

44093

GSK Investigational Site, Nantes

105275

GSK Investigational Site, Moscow

115478

GSK Investigational Site, Moscow

194291

GSK Investigational Site, Saint Petersburg

194354

GSK Investigational Site, Saint Petersburg

196240

GSK Investigational Site, Saint Petersburg

426063

GSK Investigational Site, Izhevsk

432063

GSK Investigational Site, Ulyanovsk

650000

GSK Investigational Site, Kemerovo

1105 AZ

GSK Investigational Site, Amsterdam

M23 9LT

GSK Investigational Site, Wythenshawe

LE3 9QP

GSK Investigational Site, Leicester

L7 8XP

GSK Investigational Site, Liverpool

B9 5SS

GSK Investigational Site, Birmingham

BD9 6RJ

GSK Investigational Site, Bradford

B15 2GW

GSK Investigational Site, Edgbaston